TrialThe Lancet. Oncology2014

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Grant A McArthur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.